Seeking Alpha


Send Message
View as an RSS Feed
View drdon's Comments BY TICKER:
Latest  |  Highest rated
  • Update: Questcor Shareholders Are The Net Gainers Of Acquisition Deal [View article]
    As a long term holder of QCOR absolutely thrilled. Bought more MNK yesterday as soon as the cash was freed up. MNK has excellent long term positive potential.
    Aug 19 08:54 AM | Likes Like |Link to Comment
  • Mallinckrodt Is Like Steak - Very Tasty [View article]
    EXP, as always you have done your "homework" and presented an overall picture of the proposed merger and the 2 companies, QCOR and MNK. The chatter from the shorts has gotten nowhere these days because the stocks of both companies are in strong hands. The big shorts like Tillson and Einhorn have premises that have been discredited. The pesky shorts that are still fluttering about like ravin raven are looking more stupid and obtuse than ever before. This, in my estimation, is a grand-slam that rarely comes around in one's lifetime of investing. This should be a very interesting week, wouldn't you agree? Let's all keep our eye on the "bird".
    Aug 10 09:58 AM | 3 Likes Like |Link to Comment
  • Mallinckrodt raises guidance after fiscal Q3 results [View news story]
    Here is the company's statement. SA editors you need to get your act together. You keep losing credibility..

    Looking ahead, the company now expects adjusted earnings per share in the range of $4.00 - $4.30, up from the prior range of $3.30 - $3.60. Revenue forecast was raised to $2.35 billion - $2.45 billion, from the previous forecast of $2.28 billion - $2.38 billion. Analysts expect earnings per share of $3.53 on revenues of $2.38 billion.
    Aug 7 08:52 AM | 5 Likes Like |Link to Comment
  • Questcor Pharmaceuticals beats by $0.11, beats on revenue [View news story]
    Where are you today ravin Raven? Where is your beak inserted at this moment? You going to be partying with Whitney Tilson? Bye, bye birdy!
    Jul 24 09:20 AM | 1 Like Like |Link to Comment
  • Acthar's Future Could Be An Adverse Event For Mallinckrodt [View article]
    H'man you speak the real truth. I have been trying to refute the shorty thesis of executives "dumping" stock wherever I can. They use scare tactics and do not present the truth. By now the stock is in strong hands and these frivolous short attacks do little to change the realities of this growth story.
    Jul 19 09:53 AM | 1 Like Like |Link to Comment
  • Acthar's Future Could Be An Adverse Event For Mallinckrodt [View article]
    Gee it looks like and smells like the author might just be invested in Shkreli's toy company, Retrophin. ( It will be very interesting to see the safety data on Retrophin's RE-034, as well as the data on any of the half-dozen other ACTH analogs that Retrophin (OTC:RTRX) says are in development.) More importantly another desperate attempt to salvage a beaten down short position. Same old, same old.
    Jul 17 02:31 PM | 3 Likes Like |Link to Comment
  • Questcor's Own Data Blatantly Shows A 31% Decline In Net Sales Of Acthar By Aetna, With Other Insurers Following Suit - Mallinckrodt Shareholders, Pay Attention [View article]
    Still at it Crowman! Now you have Medicare dropping coverage. The desperation on your part just shines its way thru. No one with 1/2 a brain takes anything you write seriously. I guess those penny a click earnings are helping to keep you in birdseed. You misrepresent, misconstrue and are downright redundant. Nothing new, something old.
    Jul 15 04:44 PM | 4 Likes Like |Link to Comment
  • Dumb Investment Of The Week: Mallinckrodt Plc [View article]
    The author may be related to the genre Parrot aka Raven. Same invalid arguments mouthed off by a community of shorts who are being decimated. Same old same old!
    Jul 15 04:31 PM | 3 Likes Like |Link to Comment
  • Questcor's Acthar: Refuting A Long's Optimism With Irrefutable Facts [View article]
    Hey my fine feathered friend a lesson in grammar...perhaps you want to edit your topical headline and change refutable to irrefutable. By the way my fine featherless friend did you just happen to notice the closing price...$93.49???? That too is irrefutable. Counting your pennies are you?
    Jul 10 04:45 PM | Likes Like |Link to Comment
  • Questcor's Acthar: Refuting A Long's Optimism With Irrefutable Facts [View article]
    $93.15 as I write crowman. Your article is spot on...moves the pps up every time. When is your next fictional article coming? Hope you are saving the pennies you get for each viewer.
    Jul 10 02:19 PM | 2 Likes Like |Link to Comment
  • Questcor's Acthar: Refuting A Long's Optimism With Irrefutable Facts [View article]
    That large increase in insider selling...don't you shorts read anything or do you think most shareholders are as stupid as you are? Did you never hear of stock options given out by almost all publicly traded corporations? So once and for all the exec's exercise their right to buy shares at low price and sell at prevailing higher price. None have dipped into their underlying stock holdings. So gat over it.
    As to this article by non other than the Birdman it's just another rehash of the same old, same old. Raven don't you ever tire of writing these tripey articles?
    Jul 10 01:31 PM | 4 Likes Like |Link to Comment
  • Questcor's Acthar Gel: Clinical Usage Suggests Efficacy [View article]
    The Birdbrain (QTR) is penning a piece now...time to buy! He/she is consistently wrong. Hey Birdman when you gonna write under your real name???

    The article is a logically and realistically written piece. Well done!
    Jul 10 09:03 AM | 8 Likes Like |Link to Comment
  • Questcor And Mallinckrodt: The Good, The Bad, And The Ugly [View article]
    I can only say that the author's piece shows intelligent and thorough examination of both QCOR and MNK. There is no hysterical negativity and arm bashing seen with anything relating to a short bash. Kudos for reiterating what we long term holders already know. This is an excellent piece for any newbies to read. Thanks.
    Jun 30 06:25 PM | 15 Likes Like |Link to Comment
  • Hey Mallinckrodt, Pay Close Attention - UnitedHealth Just Slammed Questcor's Acthar [View article]
    How's your short doing Parrot head? Q up to $92.38 as I write. You are a most influential bird...more like a turkey. Wrong in every aspect!
    Jun 30 03:35 PM | 3 Likes Like |Link to Comment
  • The FDA Owes Us An Answer On Questcor's Acthar [View article]
    Citron's only objective was to sow doubt in the minds of stockholders so Andy Left could start another bear raid. It doesn't work anymore. The stock is in strong hands and we longs are onto all the machinations of the shorties. They are going down and you, Raven, should take your medicine and move on. You made a monumental mistake following fraudster Left.
    Jun 26 09:13 AM | 1 Like Like |Link to Comment